EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera

Keita Kirito, Yuka Sugimoto, Akihiko Gotoh, Katsuto Takenaka, Michiko Ichii, Tadaaki Inano, Shuichi Shirane, Masafumi Ito, Oleh Zagrijtschuk, Albert Qin, Hiroaki Kawase, Toshiaki Sato und 2 weitere

International Journal of Hematology · 2024-12 · 120 (6) · 675-683

DOI: 10.1007/s12185-024-03846-5 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Hematology, online erschienen am 03.10.2024. Verfasst von Keita Kirito und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan. kirito@yamanashi.ac.jp. Hauptthemen laut MEDLINE: Interferon alpha-2, Interferon-alpha, Janus Kinase 2, Polycythemia Vera. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PharmaEssentia Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ropeginterferon alfa-2b (ropegIFN), a new-generation interferon-based agent, has been approved in Japan for patients with polycythemia vera (PV) who are ineligible for or respond inadequately to conventional treatment. However, long-term outcomes with ropegIFN in Japanese patients have not been reported. This extension of a phase 2 study of ropegIFN in Japanese patients with PV aimed to determine its long-term safety/efficacy, and changes over time in JAK2 V617F allele burden. Here, we report data from the phase 2 study and subsequent extension over a period of 36 months. The primary endpoint was the complete hematologic response (CHR) maintenance rate without phlebotomy (hematocrit value < 45% without phlebotomy during the previous 12 weeks, platelet count ≤ 400 × 10 9 /L, and white blood cell count ≤ 10 × 10 9 /L). The CHR maintenance rates were 8/27 (29.6%), 18/27 (66.7%), and 22/27 (81.5%) at 12, 24, and 36 months, respectively. No thrombotic or hemorrhagic events occurred. The median allele burden change from baseline was − 74.8% at 36 months. All patients experienced adverse events; 25/27 (92.6%) experienced adverse drug reactions (ADRs), but no serious ADRs or deaths occurred. This interim analysis demonstrated the safety and efficacy of ropegIFN over 36 months in Japanese patients with PV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon alpha-2Interferon-alphaJanus Kinase 2Polycythemia VeraPolyethylene GlycolsRecombinant ProteinsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAllelesEast Asian PeopleJapanTime FactorsTreatment Outcome

Stichwörter der Autor:innen

JAK2 V617F allele burdenHematologic responseMolecular responsePolycythemia veraRopeginterferon alfa-2b

Substanzen

Interferon alpha-2Interferon-alphaJAK2 protein, humanJanus Kinase 2peginterferon alfa-2bPolyethylene GlycolsRecombinant Proteins

Autor:innen und Institutionen

  • Department of Hematology and Oncology, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan. kirito@yamanashi.ac.jp.
  • Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
  • Department of Hematology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
  • Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan.
  • Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Department of Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Förderung

  • PharmaEssentia Corporation

Zitieren

APA

Kirito, K., Sugimoto, Y., Gotoh, A., Takenaka, K., Ichii, M., Inano, T., Shirane, S., Ito, M., Zagrijtschuk, O., Qin, A., Kawase, H., Sato, T., Komatsu, N., & Shimoda, K. (2024). Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera. International Journal of Hematology, 120(6), 675-683. https://doi.org/10.1007/s12185-024-03846-5

Vancouver

Kirito K, Sugimoto Y, Gotoh A, Takenaka K, Ichii M, Inano T, et al. Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera. International Journal of Hematology. 2024;120(6):675-683. doi:10.1007/s12185-024-03846-5

BibTeX
@article{Kirito2024,
  author = {Kirito, Keita and Sugimoto, Yuka and Gotoh, Akihiko and Takenaka, Katsuto and Ichii, Michiko and Inano, Tadaaki and Shirane, Shuichi and Ito, Masafumi and Zagrijtschuk, Oleh and Qin, Albert and Kawase, Hiroaki and Sato, Toshiaki and Komatsu, Norio and Shimoda, Kazuya},
  title = {Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera},
  journal = {International Journal of Hematology},
  year = {2024},
  volume = {120},
  number = {6},
  pages = {675--683},
  doi = {10.1007/s12185-024-03846-5}
}
Kostenlos starten →